Skip to content

Vivani Medical VANI Restricted Cash

Restricted Cash at other companies

Altimmune logo
AltimmuneALT
$42K0.0%
Wave Life Sciences logo
Wave Life SciencesWVE
$3.82M+1.1%
Prime Medicine logo
Prime MedicinePRME
$13.69M-2.6%

Other financials

Income statement

See full
Revenue-
Gross profit$130.0K
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%
Free cash flow-$6.2M-19.9%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%
Operating margin-1,004.9%
Net margin-994.1%
FCF margin-832.3%

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity-0.7×
Current ratio3.2×+0.8×

Where this comes from

Reported directly by Vivani Medical in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue.

The official record: Vivani Medical’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's restricted cash?
Vivani Medical (VANI) reported restricted cash of $1.3M in Q4 2025.
What is the long-term trend for Vivani Medical's restricted cash?
Over 3 years (2022 to 2025), Vivani Medical's restricted cash has grown at a -2.4% compound annual growth rate (CAGR), from $1.4M to $1.3M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.